Fig. 2From: Pioglitazone and PPAR-γ modulating treatment in hypertensive and type 2 diabetic patients after ischemic stroke: a national cohort studyComparison of the cumulative incidence of recurrent ischemic stroke between pioglitazone and non-pioglitazone groups in the propensity score matched cohort. The curves show lower risks of recurrent ischemic stroke in the pioglitazone groupBack to article page